Drugs / Dichloroacetate
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT02690285 | Mar 2016 → May 2017 | — | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT01807702 | Mar → Jul 2013 | — | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT01123005 | Dec 2010 → Aug 2015 | neoplasm | Stanford University | Terminated | No outcome recorded |
| Phase 1 | NCT01163487 | Aug 2010 → Feb 2015 | head and neck cancer | Daniel T. Chang | Completed | No outcome recorded |
| Phase 1 | NCT00703859 | Jul 2008 → Jan 2010 | glioblastoma | AHS Cancer Control Alberta | Withdrawn | No outcome recorded |
| Phase 1 | NCT00566410 | Dec 2007 → Mar 2013 | neoplasm | AHS Cancer Control Alberta | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01128270 | Apr 2010 → Oct 2012 | — | University of Florida | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01029925 | Dec 2009 → Aug 2011 | breast cancer, lung cancer | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00540176 | Oct 2007 → Aug 2009 | malignant glioma | University of Alberta | Completed | No outcome recorded |
| Phase 2 | NCT00068913 | Mar 2000 → ? | MELAS syndrome | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05695027 | Mar 2023 → Aug 2027 expected | open-angle glaucoma | Columbia University | Active not recruiting | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT04046081 | Nov 2019 → Sep 2021 | endometriosis | University of Edinburgh | Completed | No outcome recorded |
| — | NCT00865514 | Aug 2011 → Jan 2012 | — | University of Florida | Terminated | No outcome recorded |
| — | NCT00874276 | Aug 2009 → Nov 2012 | lactic acidosis | University of Florida | Completed | No outcome recorded |
| — | NCT00031161 | Sep 2001 → Sep 2005 | lactic acidosis | University of Florida | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT01797276 | — | inborn mitochondrial metabolism disorder | University of Florida | No longer available | No outcome recorded |
| — | NCT06931262 | — | pyruvate dehydrogenase deficiency | Saol Therapeutics Inc | Available | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05317455 Comparator | May 2025 → May 2027 expected | type 1 diabetes mellitus | Yale University | Recruiting | No outcome recorded |
| Phase 0 | NCT03356457 Comparator | Nov 2017 → Mar 2019 | hyperglycemia | Yale University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT01111097 Comparator | Apr 2010 → Mar 2014 | brain neoplasm, glioblastoma | University of Florida | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05120284 Comparator | Jul 2022 → Jul 2026 overdue | glioblastoma | University of Florida | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00604331 Comparator | Aug 2008 → Jul 2009 | acute myocardial infarction, cardiogenic shock, heart failure | Herzzentrum Goettingen | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02616484 Comparator | Jul 2020 → Aug 2025 overdue | pyruvate dehydrogenase deficiency | Saol Therapeutics Inc | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02469337 Comparator | May 2012 → Jun 2017 | — | University of Nottingham | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dichloroacetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00874276 ↗ |
| Known as | DCA | “Dichloroacetate (DCA) is a highly bioavailable small molecule that inhibits pyruvate dehydrogenase kinase, promoting glucose oxidation and reversing the glycolytic phenotype in...” PMID 24442098 ↗ Jan 20148“At least one week following the first admission subjects will return to repeat the above procedure and receive 25mg of dichloroacetate (DCA) one hour before receiving the pyruvate.” NCT01807702 ↗ “Dichloroacetate (DCA) is a small molecule that has been used for years to treat lactic acidosis and rare metabolic disorders in humans.” NCT00566410 ↗ “Dichloroacetate (DCA, an inhibitor of the mitochondrial pyruvate dehydrogenase kinase)” NCT00540176 ↗ “Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.” NCT02690285 ↗ “Dichloroacetate (DCA)” NCT02616484 ↗ “Dichloroacetate (DCA)” NCT00703859 ↗ “Dichloroacetate (DCA)” NCT00874276 ↗ “Dichloroacetate (DCA)” NCT06931262 ↗ |
| Known as | Pyruvate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05695027 ↗ |
| Action | Inhibit | “inhibition of PDHK by DCA” NCT00566410 ↗ |
| Modality | Small molecule | “DCA is also a very small molecule” NCT00540176 ↗ |
| Route | Oral | “DCA will be given orally” NCT00540176 ↗ |
| Target | GSTZ1 | “DCA is a mechanism-based inhibitor of GSTZ1” NCT02690285 ↗ |